Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.

NCT00540150 Phase 3 COMPLETED

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.

Details

Lead sponsor	Johann Wolfgang Goethe University Hospital
Phase	Phase 3
Status	COMPLETED
Enrolment	34
Start date	2004-05
Completion	2005-03

Conditions

• Immunotherapy

Interventions

• specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)

Primary outcomes

• Safety of the shortened specific immunotherapy. — may 2004 - march 2005

Countries

Germany